LOW-DOSE METHOTREXATE AND DOXORUBICIN IN HORMONE-RESISTANT PROSTATIC-CANCER

被引：3
|
作者：
SMITH, MF
LAWSON, AH
KIRK, D
KAYE, SB
机构：
[1] Department of Urology, Law Hospital, Carluke
来源：
BRITISH JOURNAL OF UROLOGY | 1990年 / 65卷 / 05期
关键词：
D O I：
10.1111/j.1464-410X.1990.tb14798.x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Summary— A group of 24 patients, all of whom had progressive disease following initial hormone therapy for advanced prostatic carcinoma, were given intravenous methotrexate (30 mg/m2) and doxorubicin (15 mg/m2) at 2‐week intervals for a planned 6‐treatment course. Seventeen patients completed the full course. Assessment included “quality of life” criteria, using the subjective assessment of performance status, severity of pain and analgesic consumption. Over half of the patients improved in each of these modalities and 8 (33%) improved in all 3. As toxicity was acceptable, low dose chemotherapy may have a part to play in these patients who present a difficult management problem. © 1990 British Journal of Urology
引用
收藏
页码：513 / 516
页数：4
相关论文
共 50 条
  • [1] FLUTAMIDE IN HORMONE-RESISTANT PROSTATIC-CANCER
    FOSSA, SD
    HOSBACH, G
    PAUS, E
    JOURNAL OF UROLOGY, 1990, 144 (06): : 1411 - 1414
  • [2] A RANDOMIZED STUDY ON HORMONE-RESISTANT PROSTATIC-CANCER - ESTRAMUSTINE PHOSPHATE VERSUS LOW-DOSE EPIRUBICIN WITH OR WITHOUT MEDROXYPROGESTERONE ACETATE
    TVETER, KJ
    HAGEN, S
    HOLME, I
    KLEPP, O
    KLOSTER, SE
    MURI, O
    POULSEN, C
    SANDER, S
    SIVERTSEN, S
    URNES, T
    OGREID, P
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1990, 24 (04): : 243 - 247
  • [3] AMINOGLUTETHIMIDE IN THE MANAGEMENT OF ADVANCED HORMONE-RESISTANT PROSTATIC-CANCER
    RAGHAVAN, D
    HARNETT, P
    PEARSON, B
    CATERSON, I
    COOREY, GJ
    ROGERS, J
    COATES, A
    BOULAS, J
    BRITISH JOURNAL OF UROLOGY, 1986, 58 (01): : 90 - 90
  • [4] SEQUENTIALLY ALTERNATING HORMONE CHEMOTHERAPY WITH HIGH-DOSE MEDROXY-PROGESTERONE ACETATE AND LOW-DOSE EPIRUBICIN FOR THE TREATMENT OF HORMONE-RESISTANT METASTATIC PROSTATIC-CANCER
    KONTTURI, M
    SOTARAUTA, M
    TAMMELA, T
    LUKKARINEN, O
    ROMPPAINEN, ML
    GROHN, P
    EUROPEAN UROLOGY, 1988, 15 (1-2) : 43 - 47
  • [5] CHEMOTHERAPY OF HORMONE-RESISTANT STAGE-D PROSTATIC-CANCER
    SCHMIDT, JD
    JOURNAL OF UROLOGY, 1980, 123 (06): : 797 - 805
  • [6] WEEKLY LOW-DOSE ADRIAMYCIN IN HORMONE-RESISTANT METASTATIC CANCER OF THE PROSTATE
    FOSSA, SD
    URNES, T
    KAALHUS, O
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1987, 21 (01): : 13 - 16
  • [7] HIGH-DOSE MEDROXYPROGESTERONE ACETATE (MPA) VERSUS PREDNISOLONE (P) IN HORMONE-RESISTANT PROSTATIC-CANCER
    FOSSA, SD
    OGREIDE, P
    HAVELAND, H
    JANSEN, J
    PROSTATE, 1983, 4 (06): : 666 - 666
  • [8] CYTOSTATIC TREATMENT OF HORMONE-RESISTANT PROSTATIC-CANCER WITH 4-EPIRUBICIN (FARMORUBICIN)
    HUBMAN, R
    HAIDER, A
    AKTUELLE UROLOGIE, 1990, 21 : 18 - 21
  • [9] HIGH-DOSE MEDROXYPROGESTERONE ACETATE VERSUS PREDNISOLONE IN HORMONE-RESISTANT PROSTATIC-CANCER - A PILOT-STUDY
    FOSSA, SD
    JAHNSEN, JU
    KARLSEN, S
    OGREID, P
    HAVELAND, H
    TROVAG, A
    EUROPEAN UROLOGY, 1985, 11 (01) : 11 - 16
  • [10] QUALITY OF LIFE IN PATIENTS WITH MUSCLE-INFILTRATING BLADDER-CANCER AND HORMONE-RESISTANT PROSTATIC-CANCER
    FOSSA, SD
    AARONSON, N
    DASILVA, FC
    DENIS, L
    NEWLING, D
    HOSBACH, G
    KAALHUS, O
    EUROPEAN UROLOGY, 1989, 16 (05) : 335 - 339
12345